Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Marek Cholody?

Marek Cholody

Vice President of Chemistry

Actokine Therapeutics

HQ Phone:  (617) 797-7693

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Actokine Therapeutics

12 Middlesex Rd # 411

Chestnut Hill, Massachusetts,02467

United States

Company Description

Drug Discovery Biotech for New Therapeutic Indications... more.

Find other employees at this company (11)

Web References(4 Total References)


Actokine Therapeutics

www.actokine.com [cached]

Vice President of Chemistry- Marek Cholody, PhD
Vice President of Chemistry - Marek Cholody, PhD Dr. Cholody has been involved in drug discovery for over 20 years. Upon completion of his PhD in Medicinal Chemistry at the Technical University of Gdansk, Poland, he joined the faculty of the Department of Pharmaceutical Technology and Biochemistry where he conducted research focused on the design and synthesis of small molecule anticancer agents. This led to the discovery of a new class of drugs - the imidazoacridones. The leading compound in this class, C-1311, is presently in Phase 2 clinical trials under the name Symadex. In 1993, Dr. Cholody joined the Molecular Aspects of Drug Design team at the National Cancer Institute, where he discovered and developed two new classes of potential anticancer and anti-AIDS agents. In 2001, he joined Avalon Pharmaceuticals as a Research Group Leader in the Medicinal Chemistry Department where he was instrumental in establishing and validating Avalon's gene expression-based drug discovery platform. His work at Avalon led to AVN316 which was nominated as clinical candidate in company's beta-catenin program. Dr. Cholody is an expert in DNA-interacting anticancer agents. He has published 26 papers and has 9 issued patents on anticancer drugs.


Actokine Therapeutics

www.actokine.com [cached]

Vice President of Chemistry- W. Marek Cholody, PhD
Vice President of Biologics - Green Zhang, PhD Vice President of Chemistry - W. Marek Cholody, PhD Dr. Cholody has been involved in drug discovery for over 20 years. Upon completion of his PhD in Medicinal Chemistry at the Technical University of Gdansk, Poland, he joined the faculty of the Department of Pharmaceutical Technology and Biochemistry where he conducted research focused on the design and synthesis of small molecule anticancer agents. This led to the discovery of a new class of drugs - the imidazoacridones. The leading compound in this class, C-1311, is presently in Phase 2 clinical trials under the name Symadex. In 1993, Dr. Cholody joined the Molecular Aspects of Drug Design team at the National Cancer Institute, where he discovered and developed two new classes of potential anticancer and anti-AIDS agents. In 2001, he joined Avalon Pharmaceuticals as a Research Group Leader in the Medicinal Chemistry Department where he was instrumental in establishing and validating Avalon's gene expression-based drug discovery platform. His work at Avalon led to AVN316 which was nominated as clinical candidate in company's beta-catenin program. Dr. Cholody is an expert in DNA-interacting anticancer agents. He has published 26 papers and has 9 issued patents on anticancer drugs.


International Drug Discovery Science and Technology (IDDST) 2008

www.iddst.com [cached]

Dr. Wieslaw Marek Cholody, Research Group Leader, Avalon Pharmaceuticals, Inc, USA


www.iddst.com

Dr. Wieslaw Marek Cholody, Research Group Leader, Avalon Pharmaceuticals, Inc, USA


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory